DAFNA Capital Management LLC
Position in RAPP — Rapport Therapeutics, Inc.
CIK 1389933
LOS ANGELES, CA
Position in RAPP
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$3,125,250
+$778,500 QoQ
Shares Held
75,000
0.0% QoQ
Ownership
0.156%
of shares outstanding
% of Portfolio
0.63%
of 13F equity value
Holder Rank
#53
of 159 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RAPP Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026DAFNA Capital Management LLC holds $345,637,467 across 65 Biotechnology names. RAPP ranks #20 (0.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
562,630 | $105,369,346 | |
| 2 | NKTR |
Nektar Therapeutics
|
318,380 | $22,226,107 | |
| 3 | DNLI |
Denali Therapeutics Inc.
|
739,014 | $19,007,440 | |
| 4 | IDYA |
IDEAYA Biosciences, Inc.
|
497,240 | $18,532,134 | |
| 5 | XENE |
Xenon Pharmaceuticals Inc.
|
250,772 | $15,136,597 | |
| 6 | CYTK |
Cytokinetics Inc
|
171,998 | $14,652,509 | |
| 7 | RCUS |
Arcus Biosciences, Inc.
|
441,829 | $13,621,588 | |
| 8 | ASND |
Ascendis Pharma A/S
|
48,469 | $12,927,651 |
All Filings in RAPP
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,125,250 | 75,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $2,346,750 | 75,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $2,275,500 | 75,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $2,227,500 | 75,000 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||